)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
AEON Biopharma (AEON) investor relations material
AEON Biopharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Strategic shift to a Section 351(k) biosimilar pathway for ABP-450, targeting all current and future therapeutic indications using Botox as the reference product, after discontinuing Phase 2 migraine trials to preserve cash.
Progressed toward key biosimilar milestones, including primary structure and functional analyses for ABP-450, with results expected in Q3 2025 and a Type 2a FDA meeting anticipated in Q4 2025.
Completed public offering in January 2025, raising $18.3 million, and entered into a $15 million convertible note agreement with Daewoong to support late-stage development and working capital.
Appointed Robert Bancroft as CEO in April 2025 following the resignation of the previous CEO.
ABP-450 is already approved as a biosimilar in India, Mexico, and the Philippines.
Financial highlights
Net loss for Q2 2025 was $6.6 million, compared to net income of $164.1 million in Q2 2024, primarily due to non-recurring gains in the prior year.
Cash and cash equivalents totaled $8.4 million as of June 30, 2025, expected to fund operations through Q4 2025 and the planned FDA meeting.
Operating expenses for Q2 2025 were $4.3 million, with SG&A at $3.3 million and R&D at $1.1 million, reflecting a 75% year-over-year decrease in R&D due to trial wind-down.
Stockholders' deficit improved to $(15.9) million at June 30, 2025, from $(28.6) million at December 31, 2024.
Convertible notes at fair value totaled $15.2 million as of June 30, 2025, up from $11.7 million at year-end 2024.
Outlook and guidance
Sufficient cash to fund operations into Q4 2025; additional funding required for further development and to meet obligations beyond that period.
Analytical studies for biosimilar development underway, with results expected in Q3 2025 and an FDA BPD Type 2a meeting planned for Q4 2025.
No revenue expected until regulatory approval and commercialization of ABP-450.
Clarify AEON's regulatory pathway for ABP-450.
Assess AEON's cash position beyond 4Q'25.
Elaborate on Daewoong's role in functional analyses.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next AEON Biopharma earnings date
Q3 202512 Nov, 2025
Next AEON Biopharma earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
AEON Biopharma Inc. is a biopharmaceutical company focused on the development of therapeutic applications for botulinum toxin. The company aims to advance treatments for a range of medical conditions, particularly in neurology and related therapeutic areas. AEON Biopharma is engaged in clinical research and regulatory processes to expand the use of botulinum toxin beyond aesthetic applications. The company is headquartered in Irvine, California, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage